Westpac Banking Corp lifted its holdings in bluebird bio Inc (NASDAQ:BLUE) by 20.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,592 shares of the biotechnology company’s stock after acquiring an additional 5,800 shares during the period. Westpac Banking Corp’s holdings in bluebird bio were worth $5,983,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in BLUE. QS Investors LLC grew its holdings in bluebird bio by 70.7% during the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 500 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its holdings in bluebird bio by 454.2% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 813 shares in the last quarter. Biondo Investment Advisors LLC acquired a new stake in bluebird bio during the 3rd quarter valued at $203,000. Fairfield Bush & CO. acquired a new stake in bluebird bio during the 2nd quarter valued at $210,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in bluebird bio during the 2nd quarter valued at $211,000.
bluebird bio Inc (NASDAQ BLUE) opened at $175.95 on Friday. bluebird bio Inc has a fifty-two week low of $64.15 and a fifty-two week high of $222.03.
In other news, insider David Davidson sold 3,522 shares of the firm’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $173.61, for a total value of $611,454.42. Following the transaction, the insider now directly owns 13,959 shares in the company, valued at approximately $2,423,421.99. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Susanna Gatti High sold 1,282 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $172.15, for a total transaction of $220,696.30. Following the completion of the transaction, the chief operating officer now owns 13,718 shares in the company, valued at $2,361,553.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 208,095 shares of company stock worth $36,841,014. Insiders own 3.90% of the company’s stock.
BLUE has been the subject of a number of recent analyst reports. Maxim Group reaffirmed a “buy” rating and set a $170.00 price target (up from $100.00) on shares of bluebird bio in a report on Monday, October 9th. Wedbush reaffirmed an “outperform” rating and set a $174.00 price target (up from $135.00) on shares of bluebird bio in a report on Thursday, November 2nd. Leerink Swann reaffirmed an “outperform” rating and set a $145.00 price target (up from $120.00) on shares of bluebird bio in a report on Friday, October 6th. Cantor Fitzgerald reaffirmed a “sell” rating and set a $58.00 price target (up from $39.00) on shares of bluebird bio in a report on Wednesday, November 1st. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $186.00 price target on shares of bluebird bio in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company. bluebird bio presently has a consensus rating of “Hold” and an average price target of $157.45.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.